$-1.07 EPS Expected for Foundation Medicine (FMI); Ormat Technologies (ORA) Has 1.3 Sentiment

October 13, 2017 - By Henry Gaston

Ormat Technologies, Inc. is engaged in the geothermal and recovered energy power business. The company has market cap of $3.12 billion. The Firm designs, develops, builds, owns and operates geothermal and recovered energy power plants. It has a 28.52 P/E ratio. The Company’s equipment manufacturing activities are located in Israel.

Analysts expect Foundation Medicine Inc (NASDAQ:FMI) to report $-1.07 EPS on November, 1.They anticipate $0.17 EPS change or 18.89% from last quarter’s $-0.9 EPS. After having $-1.24 EPS previously, Foundation Medicine Inc’s analysts see -13.71% EPS growth. About 19,063 shares traded. Foundation Medicine Inc (NASDAQ:FMI) has risen 124.70% since October 13, 2016 and is uptrending. It has outperformed by 108.00% the S&P500.

Among 9 analysts covering Foundation Medicine (NASDAQ:FMI), 1 have Buy rating, 0 Sell and 8 Hold. Therefore 11% are positive. Foundation Medicine had 12 analyst reports since July 30, 2015 according to SRatingsIntel. Benchmark downgraded the shares of FMI in report on Thursday, November 3 to “Hold” rating. As per Monday, September 14, the company rating was initiated by BTIG Research. The rating was downgraded by JMP Securities on Thursday, July 30 to “Market Perform”. On Wednesday, September 21 the stock rating was maintained by UBS with “Neutral”. BTIG Research upgraded the shares of FMI in report on Monday, May 15 to “Buy” rating. Wells Fargo downgraded the shares of FMI in report on Wednesday, September 16 to “Market Perform” rating. On Tuesday, March 7 the stock rating was upgraded by Janney Capital to “Neutral”. BTIG Research downgraded the shares of FMI in report on Wednesday, November 4 to “Neutral” rating.

Foundation Medicine, Inc. is a molecular information company. The company has market cap of $1.60 billion. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It currently has negative earnings. It is engaged in the business of delivering molecular information about cancer to its customers.

Investors sentiment increased to 1.79 in Q2 2017. Its up 0.93, from 0.86 in 2017Q1. It is positive, as 8 investors sold Foundation Medicine Inc shares while 20 reduced holdings. 18 funds opened positions while 32 raised stakes. 9.72 million shares or 8.41% more from 8.97 million shares in 2017Q1 were reported. Bnp Paribas Arbitrage Sa stated it has 1,515 shares. Sg Americas Securities Lc owns 0% invested in Foundation Medicine Inc (NASDAQ:FMI) for 4,745 shares. Amp Capital Ltd reported 6,020 shares. Next Fincl Group holds 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI) for 1,400 shares. Dekabank Deutsche Girozentrale reported 0.01% in Foundation Medicine Inc (NASDAQ:FMI). Strs Ohio holds 17,700 shares or 0% of its portfolio. Quantitative Inv Management Limited Liability Company has 0.03% invested in Foundation Medicine Inc (NASDAQ:FMI). Nationwide Fund Advsrs stated it has 7,791 shares. Meeder Asset Mgmt invested 0% in Foundation Medicine Inc (NASDAQ:FMI). Park Circle invested in 1.11% or 50,000 shares. Deutsche Financial Bank Ag has 23,379 shares. 141,473 were reported by Geode Cap Mgmt Lc. State Board Of Administration Of Florida Retirement Systems reported 0% in Foundation Medicine Inc (NASDAQ:FMI). Proshare Advsr Ltd Llc owns 19,562 shares. Needham Investment Management Lc holds 0.61% in Foundation Medicine Inc (NASDAQ:FMI) or 57,500 shares.

Since January 1, 0001, it had 0 buys, and 11 selling transactions for $3.95 million activity.

Analysts await Ormat Technologies, Inc. (NYSE:ORA) to report earnings on November, 6. They expect $0.49 earnings per share, down 12.50% or $0.07 from last year’s $0.56 per share. ORA’s profit will be $24.44 million for 31.92 P/E if the $0.49 EPS becomes a reality. After $0.58 actual earnings per share reported by Ormat Technologies, Inc. for the previous quarter, Wall Street now forecasts -15.52% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com